Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation.
The objective of this study was to establish effective postoperative analgesia for Dark Agouti rats undergoing liver transplantation with minimal additional stress due to handling and no adverse effect on transplant outcome. Oral administration of buprenorphine (0.5 mg/kg/dose) or aspirin (100 mg/kg/dose) in raspberry-flavoured gelatine were compared to controls receiving no treatment or plain gelatine. The drugs were presented five times: immediately on recovery from anaesthesia and at 12 h intervals thereafter. All rats underwent right nephrectomy and replacement of their liver by an arterialized liver isograft preserved optimally for 24 h. All groups had reversible hepatic damage, lost weight and demonstrated severely reduced dark cycle activity after surgery. Neither treatment appeared to ameliorate the loss of body weight that probably reflected hepatic insufficiency during the first week as well as pain and surgical stress. In the second week, when liver function was 'normal', rats began to regain weight at the pre-transplant rate. Aspirin treatment significantly increased activity during the first and second dark cycles after surgery, whereas buprenorphine significantly increased activity during the second dark cycle only. Neither drug had any apparent adverse effects on the rats or on graft function. Postoperative oral administration of aspirin should be incorporated into future programmes of liver transplantation in rodents. More effective treatment in the immediate postoperative period may require oral administration of analgesia prior to surgery or a single subcutaneous injection of an analgesic agent on completion of surgery in addition to postoperative oral administration of aspirin.
Jablonski
P
P
Monash University, Department of Surgery, Monash Medical Centre, Clayton, Australia.
Howden
B O
BO
D000204:Activity Cycles / Q000187:drug effects / Q000502:physiology; D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002047:Buprenorphine / Q000008:administration & dosage / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D005260:Female; D006498:Hepatectomy / Q000662:veterinary; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D008111:Liver Function Tests / Q000662:veterinary; D016031:Liver Transplantation / Q000502:physiology / Q000662:veterinary*; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009392:Nephrectomy / Q000662:veterinary; D011183:Postoperative Complications / Q000517:prevention & control / Q000662:veterinary; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000701:Analgesics, Opioid; D002047:Buprenorphine; D003404:Creatinine; D001241:Aspirin